Published April 7, 2022 By Vanessa Doctor, RN BioSpace Shares in Acadia Pharmaceuticals rose 5.71% to $27.22 per share at the close of NASDAQ Wednesday on positive late-stage data from the study of an investigational treatment for Rett syndrome. The company presented an update on its Phase III LAVENDER study of trofinetide for Rett syndrome at the American Academy […]

Acadia Pharmaceuticals Inc. and Neuren Pharmaceuticals Limited announced that the U.S. Food and Drug Administration granted Rare Pediatric Disease designation to trofinetide for the treatment of Rett syndrome, a serious and rare neurological disorder.